Clinical Trials Sponsored by SanBio, Inc.

Total 36100 results

Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PLX3397)

Tenosynovial Giant Cell Tumor

Taiwan, China
Duke University
Genentech, Inc.; Daiichi Sankyo, Inc.; American Heart Association; Janssen, LP

Completed

Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS)

Stroke | Intracerebral Hemorrhage | Cerebrovascular Stroke

United States
Icahn School of Medicine at Mount Sinai
Daiichi Sankyo, Inc.; Accumetrics, Inc.

Completed

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition (TRIAGE)

Aspirin | Percutaneous Coronary Intervention | Dual Antiplatelet Therapy | Clopidogrel

United States
Beijing Sanbo Brain Hospital

Recruiting

Post-neurosurgical Respiratory Muscle Dysfunction

Pulmonary Complication | Neurosurgery | Diaphragm Issues

China
Beijing Sanbo Brain Hospital

Recruiting

Retrospective Study of Germ Cell Tumors of the Central Nervous System

Germ Cell Tumor of CNS

China
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

Japan, United States
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
timkl
Sanoia

Recruiting

Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop. (PRO-DIAB-1)

Diabetes Mellitus, Type 1

France
Daiichi Sankyo

Recruiting

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Netherton Syndrome

France
LianBio LLC

Recruiting

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Advanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung Cancer

China
SymBio Pharmaceuticals

Recruiting

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

BK Virus Infection | Kidney Transplantation | Nephropathy

Australia, Japan
Daiichi Sankyo

Recruiting

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

COPD Exacerbation Acute

China
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
LianBio LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy

China
SymBio Pharmaceuticals

Completed

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Lymphoma, B-cell, Diffuse

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
SymBio Pharmaceuticals

Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Japan
NanoBio Corporation

Completed

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

Onychomycosis

United States, Canada
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

Recurrent Herpes Simplex Labialis

United States
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) (SHaRCS)

Recurrent Herpes Labialis

United States
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

DS-3201b in Participants With Lymphomas

Lymphoma, Malignant | Non-hodgkin Lymphoma

United States, Japan
Beijing Sanbo Brain Hospital

Recruiting

Modified CV Regimen in Optic Pathway Glioma

Optic Glioma | Pediatric Brain Tumor, Optic Nerve Glioma

China
Beijing Sanbo Brain Hospital

Recruiting

Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Recurrent Medulloblastoma

China
Beijing Sanbo Brain Hospital

Recruiting

Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas

Glioblastoma, Recurrent | Lower Grade Glioma, Recurrent

China
Beijing Sanbo Brain Hospital

Recruiting

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Primary Central Nervous System Lymphoma

China
Beijing Sanbo Brain Hospital

Suspended

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Recurrent Glioblastoma

China
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01)

Metastatic Lung Cancer

France
NYU Langone Health
Bristol-Myers Squibb; Daiichi Sankyo, Inc.

Completed

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
LianBio LLC

Recruiting

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Daiichi Sankyo

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States, Japan
LianBio LLC

Recruiting

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (FGFR)

Gastric Cancer | Solid Tumor | Gastroesophageal Junction Adenocarcinoma

China
SymBio Pharmaceuticals

Recruiting

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (ATHENA)

Adenovirus Infection

United States
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
LianBio LLC

Completed

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Blepharitis

China
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Daiichi Sankyo

Completed

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (EUROPA T-DXd)

HER2-positive Breast Cancer

Spain, Ireland, Italy
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan
SymBio Pharmaceuticals

Completed

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Radiotherapy-induced Nausea and Vomiting (RINV)

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, Diffuse

Japan, Korea, Republic of

Clinical Trials Sponsored by SanBio, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations